The Team

Dr. Andrew Regan is a Saint Barths based British born polar explorer and entrepreneur. He is the founder and Chief Executive Officer of Corvus Capital. Dr. Regan sold Hobson Plc in 1996 for £154 million by way of a recommended cash takeover. In the years after the sale of Hobson Plc, Dr. Regan continued to invest in a number of public and private companies and was a founding shareholder in ASOS, Imperial Energy, IB Daiwa and others, which each achieved valuations in excess of $1 billion.

In 2014 he was awarded a PhD for his research in writing and developing a bio- inspired algorithm for forecasting the financial markets. His thesis was “A system to predict the S&P 500 using a bio-inspired algorithm” which forecasted tomorrow’s (t+1) directional trend of the S&P 500 at 55.1% accuracy. This algorithm used a novel parallel processing approach using GPUs. Since then, Dr. Regan has written a number of additional algorithms using an implemented agentic approach.

He is passionate about the polar regions and is an accomplished polar explorer having lead a number of expeditions to both the Arctic and Antarctica.

Mr. Bligh was a co-founder of Conduit Pharmaceuticals Limited in 2019. From 2008 to 2019, Mr. Bligh worked closely with investment vehicle Corvus Capital Limited, including as a Partner, where he led a number of reverse takeover transactions, stock market listings, initial public offerings, secondary fundraisings, and merger transactions. Mr. Bligh has previously acted in the role of financial officer and has served on various boards and audit related committees throughout the earlier part of his career.

Mr. Bligh’s prior transaction experience includes advising several special purpose acquisition vehicles in listing on the London Stock Exchange, including the listing of Bermele Plc, a special purpose acquisition vehicle, and the subsequent acquisition of Bermele by East Imperial Pte. Ltd., a global purveyor of ultra-premium beverages, in June 2019; the listing of Leverett Plc, which subsequently acquired Nuformix Plc, a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing; and Cizzle Biotechnology Holdings Plc, a UK-based diagnostics developer.

He previously served as a director of Bermele Plc from June 2021 through February 2022; Mertz Plc from January 2021 through March 2022; and East Imperial Pte. Ltd. from September 2017 through April 2018. Jamie graduated from the University of Bristol with a BSc in Economics & Finance.

Chele Chiavacci Farley has served on the MURF Board since the closing of its initial public offering and currently serves as a partner and managing director of Mistral Capital International (“Mistral”), a private equity firm, since 1995. In her role as Partner and Managing Director of Mistral, Ms. Farley originates, evaluates and executes equity investment opportunities, creates and implements deal and financial structures, negotiates with banks for credit facilities, and oversees management.

Ms. Farley is the President and a member of the Board of Directors and Management Committee of Palmilla San Jose Inmobiliaria, the Master Developer of the luxury Palmilla resort development in Cabo San Lucas, Mexico. Prior to Mistral, Ms. Farley was Vice President of Tricap International from 1994 to 1995. From 1992 to 1994, Ms. Farley was an Associate at UBS Capital Corporation, and analyzed and evaluated principal investment and financing opportunities for the firm’s internal $1 billion fund. Ms. Farley began her career as a Financial Analyst in the Global Finance department – Energy and Telecom Group of Goldman, Sachs & Co.

Ms. Farley has also had an active political career. In 2020, Ms. Farley ran for election to the U.S. House of Representatives to represent New York’s 18th Congressional district. In 2018, Ms. Farley ran for election to the U.S. Senate to represent New York. Ms. Farley graduated from Stanford University with a B.S. and M.S. in Industrial Engineering. She is a member of YPO – Young Presidents’ Organization.

Mr. Fry has over 30 years’ experience in investment banking having held senior executive positions at various top-tier institutions. In 2003, Mr. Fry was appointed as Chief Executive Officer at Crosby Asset Management. He previously worked at Nomura, where he was Managing Director and European Board member, as well as a member of the risk committee and credit committee. During his time at Nomura, Mr. Fry initiated and built the Company’s Asset Investment Group, whose focus was to create specific product and strategy groups within it to invest in mis-priced and undervalued credit and equity exposures. During this period, Mr. Fry was also responsible for building Nomura’s highly regarded International Markets Division, which was responsible for all the European capital market activity in equity, fixed income and derivatives including primary origination. Prior to this, Mr. Fry spent 14 years at Credit Suisse First Boston (CSFB) trading a variety of securities including both fixed income and equities. From 1990, Mr. Fry developed CSFB’s Asset Trading Group, and as Managing Director built a team that generated significant returns over a number of years for CSFB. Mr. Fry is based in Los Angeles.

Dr. Andrew Regan is a Saint Barths based British born polar explorer and entrepreneur. He is the founder and Chief Executive Officer of Corvus Capital. Dr. Regan sold Hobson Plc in 1996 for £154 million by way of a recommended cash takeover. In the years after the sale of Hobson Plc, Dr. Regan continued to invest in a number of public and private companies and was a founding shareholder in ASOS, Imperial Energy, IB Daiwa and others, which each achieved valuations in excess of $1 billion.

In 2014 he was awarded a PhD for his research in writing and developing a bio- inspired algorithm for forecasting the financial markets. His thesis was “A system to predict the S&P 500 using a bio-inspired algorithm” which forecasted tomorrow’s (t+1) directional trend of the S&P 500 at 55.1% accuracy. This algorithm used a novel parallel processing approach using GPUs. Since then, Dr. Regan has written a number of additional algorithms using an implemented agentic approach.

He is passionate about the polar regions and is an accomplished polar explorer having lead a number of expeditions to both the Arctic and Antarctica.

Mr. Bligh was a co-founder of Conduit Pharmaceuticals Limited in 2019. From 2008 to 2019, Mr. Bligh worked closely with investment vehicle Corvus Capital Limited, including as a Partner, where he led a number of reverse takeover transactions, stock market listings, initial public offerings, secondary fundraisings, and merger transactions. Mr. Bligh has previously acted in the role of financial officer and has served on various boards and audit related committees throughout the earlier part of his career.

Mr. Bligh’s prior transaction experience includes advising several special purpose acquisition vehicles in listing on the London Stock Exchange, including the listing of Bermele Plc, a special purpose acquisition vehicle, and the subsequent acquisition of Bermele by East Imperial Pte. Ltd., a global purveyor of ultra-premium beverages, in June 2019; the listing of Leverett Plc, which subsequently acquired Nuformix Plc, a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing; and Cizzle Biotechnology Holdings Plc, a UK-based diagnostics developer.

He previously served as a director of Bermele Plc from June 2021 through February 2022; Mertz Plc from January 2021 through March 2022; and East Imperial Pte. Ltd. from September 2017 through April 2018. Jamie graduated from the University of Bristol with a BSc in Economics & Finance.

Dr. Holland brings over 20 years of experience to the CSO role at Conduit, having amassed expertise across the entire development spectrum. This includes a deep knowledge base in identifying drugs that can be applied across multiple disease states, combining research and commercial skills to advance drugs to market, and working with premier scientific thought leaders.

She has a specific focus in solid-form technology and its associated intellectual property, having held leadership positions at publicly traded companies in this space, as well as consulting roles for several pharmaceutical companies on all matters relating to solid-form technology. She has successfully shepherded multiple solid-form candidates from discovery stage into the clinic, and is the author of over 50 solid-form intellectual property patents.

Dr. Holland earned a PhD in chemistry from the University of Leeds, UK, which was sponsored by Pfizer, Inc., before starting her career at companies including Millennium Pharmaceuticals and Stylacats Limited.